Clinical Trials Logo

Coronary Vessel Anomalies clinical trials

View clinical trials related to Coronary Vessel Anomalies.

Filter by:

NCT ID: NCT05699200 Recruiting - Healthy Clinical Trials

A Study to Analyze the Role of Sympathetic Nervous System in Spontaneous Coronary Artery Dissection

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this research is to compare sympathetic function (flight or fight system) and arterial health including structure and mechanics of participants with history of spontaneous coronary artery dissection (SCAD) to age and sex matched control participants.

NCT ID: NCT04906356 Recruiting - Clinical trials for Spontaneous Coronary Artery Dissection

Canadian SCAD Study

Start date: December 1, 2018
Phase:
Study type: Observational

Natural history multicenter, prospective, observational registry with 10-year follow-up

NCT ID: NCT04850417 Not yet recruiting - Clinical trials for Spontaneous Coronary Artery Dissection

Randomized Study of Beta-Blockers and Antiplatelets in Patients With Spontaneous Coronary Artery Dissection

BA-SCAD
Start date: April 30, 2021
Phase: Phase 4
Study type: Interventional

Spontaneous coronary artery dissection (SCAD) is a cause of acute coronary syndrome (ACS). Most patients are treated with beta-blockers (BB) and antiplatelet drugs (AP) on empiric basis. The Beta-Blockers and Antiplatelet Agents in Patients with Spontaneous Coronary Artery Dissection (BA-SCAD) randomized clinical trial is an academic, pragmatic, nation-wide, prospective study developed under the auspices of the Spanish Society of Cardiology (SEC) that aims to assess the efficacy of medical therapy in SCAD patients. Using a factorial 2x2 design, patients will be randomized (1:1/1:1) to: 1) BB (yes/no) and 2) short AP regimen (1 month) vs prolonged dual AP therapy (DAPT) (12 months).Only patients with preserved left ventricular ejection fraction (LVEF) will be randomized to BB (yes/no) because patients with LVEF <40% will receive BB according to current guidelines. Likewise, only medically managed patients will be randomized to short AP therapy vs 1-year DAPT. The study will have a pragmatic, open label, blind outcomes design (PROBE). A total of 600 SCAD patients will be randomized within 2 years (300 per arm in a factorial 2x2 design). The primary efficacy endpoint will include the composite of death, acute myocardial infarction (MI), stroke, coronary revascularization, recurrent SCAD, and unplanned hospitalization for ACS or heart failure at 1 year. The primary safety endpoint will be bleeding. All patients will be clinically followed yearly. The main study will be pragmatic but a comprehensive set of additional studies (clinical, imaging, biomarkers, inflammatory, immunologic, pharmacogenetic and genetic) will be organized to ensure an holistic view on this challenging condition.

NCT ID: NCT04496687 Recruiting - Clinical trials for Spontaneous Coronary Artery Dissection

International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry

Start date: March 8, 2019
Phase:
Study type: Observational [Patient Registry]

The aim of "iSCAD," the International Spontaneous Coronary Artery Dissection (SCAD) Registry, is to serve as an internationally collaborative, multicenter registry coordinated by an experienced and centralized coordinating center in an effort to increase the pace of participant recruitment, and thereby increase statistical power of studies related to SCAD. The ultimate goal of iSCAD Registry is to facilitate the development of best practices and clinical guidelines for preventing SCAD or its recurrence. This observational study will be prospective and retrospective in its recruitment and will collect clinical information to better understand the natural history and prognosis for SCAD.

NCT ID: NCT04457544 Recruiting - Clinical trials for Spontaneous Coronary Artery Dissection

Spontaneous Coronary Artery Dissection National Swiss Registry

SwissSCAD
Start date: August 12, 2020
Phase:
Study type: Observational [Patient Registry]

Spontaneous coronary artery dissection (SCAD), is an underdiagnosed pathology, affecting predominantly young women without traditional cardiovascular risk factors and is associated with major adverse outcomes including myocardial infarction, cardiac arrest, or death. Timely diagnosis of SCAD as well as clinical follow-up are of the essence in this pathology associated with major cardiac adverse outcomes. Despite recent improvements in diagnosis and recognition of the importance of SCAD, it remains poorly studied and understood. In this context, we designed the SwissSCAD registry, a large, observational, prospective, cohort study, to describe the natural history of SCAD, its outcomes and its treatments.

NCT ID: NCT03876847 Enrolling by invitation - Clinical trials for Spontaneous Coronary Artery Dissection

Genetics of Spontaneous Coronary Artery Dissection (SCAD-INSPIRE Genetics)

SCAD-INSPIRE
Start date: October 17, 2016
Phase:
Study type: Observational

Spontaneous coronary artery dissection (SCAD) is a rare cause of coronary ischemia and infarction where a tear in blood vessel wall either restricts the flow of blood or the blood becomes trapped in between the layers of the vessel causing the vessel to impinge on the lumen and causing an obstruction or restriction of blood flow. The ultimate goal of this proposal is to further understand the risk factors leading to SCAD with a focus on familial and genetic causes of SCAD.

NCT ID: NCT03398850 Recruiting - Clinical trials for Coronary Artery Dissection, Spontaneous

Spontaneous Coronary Artery Dissection anaLysIs of the Brazilian Updated Registry

SCALIBUR
Start date: January 1, 2000
Phase: N/A
Study type: Observational [Patient Registry]

A retrospective and prospective registry will evaluate demographic and angiographic data in patients with spontaneous coronary artery dissection (SCAD) using medical records, invasive coronary angiography, intravascular imaging and/or computed multislice coronary tomography. The type of treatment applied during index hospitalization (i.e., clinical management, percutaneous coronary intervention or coronary artery bypass grafting) will be evaluated. Long-term follow-up (up to 10 years) will be also reported.

NCT ID: NCT02799186 Completed - Clinical trials for Spontaneous Coronary Artery Dissection

The Study of the Prevalence Fibromuscular Dysplasia in Patient With Haematoma or Spontaneous Coronary Artery Dissection.

DISCO
Start date: May 2016
Phase: N/A
Study type: Interventional

Spontaneous Coronary Artery Dissection (SCAD) is a rare and often misdiagnosed cause of Acute Coronary Syndrome (ACS) affecting predominantly young women without cardiovascular risk factors. The origin of SCAD remains uncertain but a strong and frequent association with Fibromuscular Dysplasia (FMD) has been recently reported based on imaging evidence only. The aim of our study is to assess the presence of FMD and its genetic determinants i in a sample for haematoma or spontaneous coronary artery dissection. From May 2016 to 2018 we plan to include prospectively and retrospectively 200 patients admitted for ACS with confirmed diagnosis of SCAD. This study will be conducted in more than 30 French interventional cardiology centers. Coronary angiograms or intracoronary imaging data will be reviewed by two experienced interventional cardiologist experts in SCAD diagnosis. For each patient a genetic analysis will be performed. A systematic screening for FMD will be realized by computed tomographic or MRI angiography of renal, cerebrovascular and iliac arteries and reviewed by two experienced radiologists. A one year follow-up is expected. This study aims to confirm the presumed association of FMD and SCAD through the exploration of several artery beds and the study of confirmed genetic determinants, which has never been described previously to our knowledge.

NCT ID: NCT02008786 Terminated - Clinical trials for Coronary Artery Dissection, Spontaneous

Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD

SAFER-SCAD
Start date: June 2014
Phase: Phase 4
Study type: Interventional

An emerging cause of heart attack in young women is a dissection (or tear) in the coronary arteries. Many of these young women continue to have chest pain long after the tear has healed and this is thought to be due to problems with their small blood vessels of the heart (or microcirculation). We want to determine whether commonly used medications for coronary artery disease including statins (for cholesterol) and angiotensin-converting enzyme inhibitors (for blood pressure) reduce chest pain and improve small vessel function in these patients.

NCT ID: NCT01967511 Recruiting - Clinical trials for Spontaneous Coronary Artery Dissection

Defining the Basis of Fibromuscular Dysplasia (FMD)

DEFINE
Start date: October 2013
Phase:
Study type: Observational

The purpose of this study has evolved and expanded since its inception. Originally the intent was to establish the functional, molecular and genetic profile of fibroblasts from Fibromuscular Dysplasia (FMD) patients as compared to carefully matched control subjects. While this remains among the objectives, the study has been expanded to undertake a fully powered cross-tissue systems genetics analysis of FMD, and now also the related arteriopathies spontaneous coronary artery dissection (SCAD) and cervical artery dissection (CvAD). The overall objective is to disclose the core biologic mechanisms of these disorders.